BDTX BLACK DIAMOND THERAPEUTICS INC Company Mergers 8-K Filing 2025 - License Agreement On March 18, 2025, Black Diamond Therapeutics entered a License Agreement with Servier Pharmaceuticals for the development and commercialization of BDTX-4933, receiving an upfront payment of $70 million and potential milestone payments up to $710 million.Get access to all SEC 8-K filings of the BLACK DIAMOND THERAPEUTICS INC